05:48 PM EDT, 05/14/2024 (MT Newswires) -- Lumos Pharma ( LUMO ) said Tuesday it completed end-of-phase 2 meeting with the US Food and Drug Administration with plans to move forward with a proposal of Phase 3 study of LUM-201, an oral growth hormone secretagogue.

The proposed 12-month trial will enroll about 150 patients and the placebo-controlled portion of the study will last six months, according to the company.

Lumos expects to start the trial in Q4, subject to the FDA's approval.